Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Liver Diseases

  Free Subscription


08.11.2021

1 Am J Gastroenterol
1 Am J Pathol
2 Anticancer Res
9 BMC Cancer
1 BMC Gastroenterol
2 Cancer Res
2 Clin Res Hepatol Gastroenterol
2 Dig Dis Sci
1 Endoscopy
4 Hepatology
8 J Gastroenterol Hepatol
16 J Hepatol
5 Minerva Gastroenterol (Torino)
2 PLoS One
1 Radiol Imaging Cancer
5 Transplantation


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Am J Gastroenterol

  1. DUONG NK, Shrestha S, Park D, Shahab O, et al
    Bristol Stool Scale as a Determinant of Hepatic Encephalopathy Management in Patients With Cirrhosis.
    Am J Gastroenterol. 2021 Nov 5. pii: 00000434-990000000-00135.
    PubMed         Abstract available


    Am J Pathol

  2. CHAO X, Wang S, Hlobik M, Ballabio A, et al
    Loss of Hepatic Transcription Factor EB Attenuates Alcohol-Associated Liver Carcinogenesis.
    Am J Pathol. 2021 Oct 27. pii: S0002-9440(21)00442.
    PubMed         Abstract available


    Anticancer Res

  3. OMIYA S, Komatsu S, Kido M, Kuramitsu K, et al
    Impact of Sarcopenia as a Prognostic Factor on Reductive Hepatectomy for Advanced Hepatocellular Carcinoma.
    Anticancer Res. 2021;41:5775-5783.
    PubMed         Abstract available

  4. IMAI N, Yokoyama S, Yamamoto K, Ito T, et al
    Safety and Efficacy of Glass Membrane Pumping Emulsification Device in Transarterial Chemoembolization for Hepatocellular Carcinoma: First Clinical Outcomes.
    Anticancer Res. 2021;41:5817-5820.
    PubMed         Abstract available


    BMC Cancer

  5. FU Y, Wei X, Han Q, Le J, et al
    Identification and characterization of a 25-lncRNA prognostic signature for early recurrence in hepatocellular carcinoma.
    BMC Cancer. 2021;21:1165.
    PubMed         Abstract available

  6. DING J, Wen Z
    Survival improvement and prognosis for hepatocellular carcinoma: analysis of the SEER database.
    BMC Cancer. 2021;21:1157.
    PubMed         Abstract available

  7. WANG F, Numata K, Takeda A, Ogushi K, et al
    Optimal application of stereotactic body radiotherapy and radiofrequency ablation treatment for different multifocal hepatocellular carcinoma lesions in patients with Barcelona Clinic Liver Cancer stage A4-B1: a pilot study.
    BMC Cancer. 2021;21:1169.
    PubMed         Abstract available

  8. BO J, Peng H, LianHua Z, Xiang F, et al
    Intraarterial contrast-enhanced ultrasound to predict the short-term tumour response of hepatocellular carcinoma to Transarterial chemoembolization with Lipiodol.
    BMC Cancer. 2021;21:1171.
    PubMed         Abstract available

  9. GAO S, Gang J, Yu M, Xin G, et al
    Computational analysis for identification of early diagnostic biomarkers and prognostic biomarkers of liver cancer based on GEO and TCGA databases and studies on pathways and biological functions affecting the survival time of liver cancer.
    BMC Cancer. 2021;21:791.
    PubMed         Abstract available

  10. VOGLHUBER T, Eitz KA, Oechsner M, Vogel MME, et al
    Analysis of using high-precision radiotherapy in the treatment of liver metastases regarding toxicity and survival.
    BMC Cancer. 2021;21:780.
    PubMed         Abstract available

  11. SUN X, Mei J, Lin W, Yang Z, et al
    Reductions in AFP and PIVKA-II can predict the efficiency of anti-PD-1 immunotherapy in HCC patients.
    BMC Cancer. 2021;21:775.
    PubMed         Abstract available

  12. SONG D, Hu Y, Diao B, Miao R, et al
    Effects of Tamoxifen vs. Toremifene on fatty liver development and lipid profiles in breast Cancer.
    BMC Cancer. 2021;21:798.
    PubMed         Abstract available

  13. WATANABE T, Tokumoto Y, Joko K, Michitaka K, et al
    AFP and eGFR are related to early and late recurrence of HCC following antiviral therapy.
    BMC Cancer. 2021;21:699.
    PubMed         Abstract available


    BMC Gastroenterol

  14. WU SY, Liao P, Yan LY, Zhao QY, et al
    Correlation of MKI67 with prognosis, immune infiltration, and T cell exhaustion in hepatocellular carcinoma.
    BMC Gastroenterol. 2021;21:416.
    PubMed         Abstract available


    Cancer Res

  15. GONZALEZ-ROMERO F, Mestre D, Aurrekoetxea I, O'Rourke CJ, et al
    E2F1 and E2F2-Mediated Repression of CPT2 Establishes a Lipid-Rich Tumor-Promoting Environment.
    Cancer Res. 2021;81:2874-2887.
    PubMed         Abstract available

  16. LULLI M, Del Coco L, Mello T, Sukowati C, et al
    DNA Damage Response Protein CHK2 Regulates Metabolism in Liver Cancer.
    Cancer Res. 2021;81:2861-2873.
    PubMed         Abstract available


    Clin Res Hepatol Gastroenterol

  17. PETA V, Zhu J, Lubman DM, Huguet S, et al
    Input of serum haptoglobin fucosylation profile in the diagnosis of hepatocellular carcinoma in patients with non-cirrhotic liver disease.
    Clin Res Hepatol Gastroenterol. 2020 Jan 18. pii: S2210-7401(19)30272.
    PubMed         Abstract available

  18. CHAIBI S, Boussier J, Hajj WE, Abitbol Y, et al
    Liver function test abnormalities are associated with a poorer prognosis in Covid-19 patients: Results of a French cohort.
    Clin Res Hepatol Gastroenterol. 2021;45:101556.
    PubMed         Abstract available


    Dig Dis Sci

  19. PODRUG K, Trkulja V, Zelenika M, Bokun T, et al
    Validation of the New Diagnostic Criteria for Clinically Significant Portal Hypertension by Platelets and Elastography.
    Dig Dis Sci. 2021 Nov 5. pii: 10.1007/s10620-021-07277.
    PubMed         Abstract available

  20. BENITEZ C
    Pressure Measurements Under Pressure: Simplifying the Diagnosis of Clinically Significant Portal Hypertension.
    Dig Dis Sci. 2021 Nov 5. pii: 10.1007/s10620-021-07283.
    PubMed        


    Endoscopy

  21. SHIRATORI Y, Yoshimoto T, Yamamoto K
    Esophageal variceal treatment using a novel Doppler probe method.
    Endoscopy. 2021;53:E419-E420.
    PubMed        


    Hepatology

  22. KONIGSHOFER P, Hofer BS, Brusilovskaya K, Simbrunner B, et al
    Distinct structural and dynamic components of portal hypertension in different animal models and human liver disease etiologies.
    Hepatology. 2021 Oct 30. doi: 10.1002/hep.32220.
    PubMed         Abstract available

  23. LAN T, Jiang S, Zhang J, Weng Q, et al
    Breviscapine Alleviates Nonalcoholic Steatohepatitis by Inhibiting TGF-beta-activated Kinase 1-dependent Signaling.
    Hepatology. 2021 Oct 30. doi: 10.1002/hep.32221.
    PubMed         Abstract available

  24. DING MJ, Fang HR, Zhang JK, Shi JH, et al
    E3 ubiquitin ligase RNF5 protects against hepatic ischemia reperfusion injury by mediating PGAM5 ubiquitination.
    Hepatology. 2021 Nov 4. doi: 10.1002/hep.32226.
    PubMed         Abstract available

  25. ROSENBLATT R, Lee H, Liapakis A, Lunsford KE, et al
    Equitable access to liver transplant: Bridging the gaps in the social determinants of health.
    Hepatology. 2021 Jun 1. doi: 10.1002/hep.31986.
    PubMed         Abstract available


    J Gastroenterol Hepatol

  26. RHODES FA, Trembling P, Panovska-Griffiths J, Tanwar S, et al
    Systematic review: Investigating the prognostic performance of four non-invasive tests in alcohol-related liver disease.
    J Gastroenterol Hepatol. 2021;36:1435-1449.
    PubMed         Abstract available

  27. LV T, Chen S, Li M, Zhang D, et al
    Regional variation and temporal trend of primary biliary cholangitis epidemiology: A systematic review and meta-analysis.
    J Gastroenterol Hepatol. 2021;36:1423-1434.
    PubMed         Abstract available

  28. KIM BH, Yu SJ, Kang W, Cho SB, et al
    Expert Consensus on the Management of Adverse Events in Patients Receiving Lenvatinib for Hepatocellular Carcinoma.
    J Gastroenterol Hepatol. 2021 Nov 1. doi: 10.1111/jgh.15727.
    PubMed         Abstract available

  29. HUANG Y, Huang F, Yang L, Hu W, et al
    Development and validation of a radiomics signature as a non-invasive complementary predictor of gastroesophageal varices and high-risk varices in compensated advanced chronic liver disease: A multicenter study.
    J Gastroenterol Hepatol. 2021;36:1562-1570.
    PubMed         Abstract available

  30. LIU D, Shen Y, Zhang R, Xun J, et al
    Prevalence and risk factors of metabolic associated fatty liver disease among people living with HIV in China.
    J Gastroenterol Hepatol. 2021;36:1670-1678.
    PubMed         Abstract available

  31. AHADI M, Molooghi K, Masoudifar N, Namdar AB, et al
    A review of non-alcoholic fatty liver disease in non-obese and lean individuals.
    J Gastroenterol Hepatol. 2021;36:1497-1507.
    PubMed         Abstract available

  32. HASSANI ZADEH S, Mansoori A, Hosseinzadeh M
    Relationship between dietary patterns and non-alcoholic fatty liver disease: A systematic review and meta-analysis.
    J Gastroenterol Hepatol. 2021;36:1470-1478.
    PubMed         Abstract available

  33. CHUN HS, Lee JS, Lee HW, Kim BK, et al
    Association between the severity of liver fibrosis and cardiovascular outcomes in patients with type 2 diabetes.
    J Gastroenterol Hepatol. 2021;36:1703-1713.
    PubMed         Abstract available


    J Hepatol

  34. GENESCA J, Abraldes JG, Bosch J
    Do we need to re-define the Baveno VI elastography criteria for compensated advanced chronic liver disease (cACLD)?
    J Hepatol. 2021;75:750-752.
    PubMed        

  35. SHAHINI E, Ahmed F
    Chronic fatigue should not be overlooked in primary biliary cholangitis.
    J Hepatol. 2021 Feb 25. pii: S0168-8278(21)00154.
    PubMed        

  36. CUCCHETTI A, Serenari M, Sposito C, Di Sandro S, et al
    Including mRECIST in the Metroticket 2.0 criteria improves prediction of hepatocellular carcinoma-related death after liver transplant.
    J Hepatol. 2020 Mar 19. pii: S0168-8278(20)30177.
    PubMed         Abstract available

  37. KOWDLEY KV, Vuppalanchi R, Levy C, Floreani A, et al
    A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis.
    J Hepatol. 2020 Mar 9. pii: S0168-8278(20)30160.
    PubMed         Abstract available

  38. HARRISON SA, Wai-Sun Wong V, Okanoue T, Bzowej N, et al
    Selonsertib for Patients with Bridging Fibrosis or Compensated Cirrhosis Due to NASH: Results from Randomized Ph III STELLAR Trials.
    J Hepatol. 2020 Mar 5. pii: S0168-8278(20)30126.
    PubMed         Abstract available

  39. SAVALE L, Guimas M, Ebstein N, Fertin M, et al
    Portopulmonary hypertension in the current era of pulmonary hypertension management.
    J Hepatol. 2020 Mar 4. pii: S0168-8278(20)30119.
    PubMed         Abstract available

  40. VAN WESSEL DBE, Thompson RJ, Gonzales E, Jankowska I, et al
    Genotype correlates with the natural history of severe bile salt export pump deficiency.
    J Hepatol. 2020 Feb 19. pii: S0168-8278(20)30105.
    PubMed         Abstract available

  41. SANGRO B, Bruix J, Chan SL, Galle PR, et al
    Immunotherapy for patients with hepatocellular carcinoma and chronic viral infections.
    J Hepatol. 2021 Nov 1. pii: S0168-8278(21)02162.
    PubMed        

  42. HAN Y, Black S, Gong Z, Chen Z, et al
    Membrane-delimited signaling and cytosolic action of MG53 preserve hepatocyte integrity during drug-induced liver injury.
    J Hepatol. 2021 Nov 1. pii: S0168-8278(21)02154.
    PubMed         Abstract available

  43. KRAGLUND F, Gantzel RH, Jepsen P, Aagaard NK, et al
    External validation of the Freiburg index of post-TIPS survival.
    J Hepatol. 2021;75:746-747.
    PubMed        

  44. MA L, Craig AJ, Heinrich S
    Hypoxia is a key regulator in liver cancer progression.
    J Hepatol. 2021;75:736-737.
    PubMed        

  45. CORPECHOT C
    Reply to: "Chronic fatigue should not be overlooked in primary biliary cholangitis".
    J Hepatol. 2021 Jun 6. pii: S0168-8278(21)00404.
    PubMed        

  46. PARK H, Yoon EL, Cho S, Nah EH, et al
    Do we need a new cut-off for FIB-4 in the metabolic dysfunction-associated fatty liver disease era?
    J Hepatol. 2021;75:725-726.
    PubMed        

  47. PAPATHEODORIDI M, Pinzani M, Tsochatzis E
    Reply to: "Do we need to re-define the Baveno VI elastography criteria for compensated advanced chronic liver disease (cACLD)?"
    J Hepatol. 2021;75:752-753.
    PubMed        

  48. BETTINGER D, Thimme R, Schultheiss M
    Reply to: Correspondence on "Refining prediction of survival after TIPS with the novel Freiburg index of post-TIPS survival".
    J Hepatol. 2021;75:749-750.
    PubMed        

  49. WANG Q, Bai W, Han G
    Freiburg index of post-TIPS survival: The first score for individual prediction and a complementary tool for risk stratification.
    J Hepatol. 2021;75:747-749.
    PubMed        


    Minerva Gastroenterol (Torino)

  50. SCIARRONE SS, Zanetto A, Russo FP, Germani G, et al
    Malnourished cirrhotic patient: what should we do?
    Minerva Gastroenterol (Torino). 2021;67:11-22.
    PubMed         Abstract available

  51. TESTINO G, Pellicano R
    Acute-on-chronic liver failure by SARS-CoV-2 in active alcohol use disorder cirrhotic patient.
    Minerva Gastroenterol (Torino). 2021;67:283-288.
    PubMed         Abstract available

  52. ZANETTO A, Barbiero G, Battistel M, Sciarrone SS, et al
    Management of portal hypertension severe complications.
    Minerva Gastroenterol (Torino). 2021;67:26-37.
    PubMed         Abstract available

  53. FERRARESE A, Sciarrone SS, Pellone M, Shalaby S, et al
    Current and future perspective on targeted agents and immunotherapies in hepatocellular carcinoma.
    Minerva Gastroenterol (Torino). 2021;67:4-10.
    PubMed         Abstract available

  54. GERMANI G, Battistella S, Ulinici D, Zanetto A, et al
    Drug induced liver injury: from pathogenesis to liver transplantation.
    Minerva Gastroenterol (Torino). 2021;67:50-64.
    PubMed         Abstract available


    PLoS One

  55. HE Y, Xu R, Peng L, Hu X, et al
    Tumor infiltrating lymphocytes associated competitive endogenous RNA networks as predictors of outcome in hepatic carcinoma based on WGCNA analysis.
    PLoS One. 2021;16:e0254829.
    PubMed         Abstract available

  56. DAYTON KA, Bril F, Barb D, Lai J, et al
    Severity of non-alcoholic steatohepatitis is not linked to testosterone concentration in patients with type 2 diabetes.
    PLoS One. 2021;16:e0251449.
    PubMed         Abstract available


    Radiol Imaging Cancer

  57. TAIJI R, Lin EY, Lin YM, Yevich S, et al
    Combined Angio-CT Systems: A Roadmap Tool for Precision Therapy in Interventional Oncology.
    Radiol Imaging Cancer. 2021;3:e210039.
    PubMed         Abstract available


    Transplantation

  58. WALLACE D, Cowling TE, Walker K, Suddle A, et al
    The Impact of Performance Status on Length of Hospital Stay and Clinical Complications Following Liver Transplantation.
    Transplantation. 2020 Oct 8. doi: 10.1097/TP.0000000000003484.
    PubMed         Abstract available

  59. CARTIN-CEBA R, Burger C, Swanson K, Vargas H, et al
    Clinical Outcomes after Liver Transplantation in Patients with Portopulmonary Hypertension.
    Transplantation. 2020 Oct 12. doi: 10.1097/TP.0000000000003490.
    PubMed         Abstract available

  60. YOELI D, Choudhury RA, Nydam TL, Pomposelli JJ, et al
    The Surge in Deceased Liver Donors Due to the Opioid Epidemic: Is It Time to Split the Difference?
    Transplantation. 2021;105:2239-2244.
    PubMed         Abstract available

  61. JAMAL M, AlMahmeed H, AlGhanem M, AlMatooq M, et al
    Organ Transplantation in Kuwait and the Recent Initiation of a Liver Program.
    Transplantation. 2021;105:2125-2127.
    PubMed        

  62. SCHLEGEL A, Foley DP, Savier E, Flores Carvalho M, et al
    Recommendations for Donor and Recipient Selection and Risk Prediction: Working Group Report From the ILTS Consensus Conference in DCD Liver Transplantation.
    Transplantation. 2021;105:1892-1903.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Liver Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: